Basilea Pharmaceutica (Switzerland) Performance
| BSLN Stock | CHF 40.60 1.50 3.56% |
The firm shows a Beta (market volatility) of 0.15, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Basilea Pharmaceutica's returns are expected to increase less than the market. However, during the bear market, the loss of holding Basilea Pharmaceutica is expected to be smaller as well. At this point, Basilea Pharmaceutica has a negative expected return of -0.19%. Please make sure to confirm Basilea Pharmaceutica's value at risk, skewness, and the relationship between the maximum drawdown and potential upside , to decide if Basilea Pharmaceutica performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Basilea Pharmaceutica AG has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors. ...more
| Begin Period Cash Flow | 66.3 M | |
| Total Cashflows From Investing Activities | 3.6 M |
Basilea |
Basilea Pharmaceutica Relative Risk vs. Return Landscape
If you would invest 4,620 in Basilea Pharmaceutica AG on August 29, 2024 and sell it today you would lose (560.00) from holding Basilea Pharmaceutica AG or give up 12.12% of portfolio value over 90 days. Basilea Pharmaceutica AG is generating negative expected returns and assumes 1.2892% volatility on return distribution over the 90 days horizon. Simply put, 11% of stocks are less volatile than Basilea, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Basilea Pharmaceutica Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Basilea Pharmaceutica's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Basilea Pharmaceutica AG, and traders can use it to determine the average amount a Basilea Pharmaceutica's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1501
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BSLN |
Estimated Market Risk
| 1.29 actual daily | 11 89% of assets are more volatile |
Expected Return
| -0.19 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Basilea Pharmaceutica is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Basilea Pharmaceutica by adding Basilea Pharmaceutica to a well-diversified portfolio.
Basilea Pharmaceutica Fundamentals Growth
Basilea Stock prices reflect investors' perceptions of the future prospects and financial health of Basilea Pharmaceutica, and Basilea Pharmaceutica fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Basilea Stock performance.
| Return On Asset | 0.0261 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 670.47 M | |||
| Shares Outstanding | 11.93 M | |||
| Price To Earning | 190.88 X | |||
| Price To Sales | 3.69 X | |||
| Revenue | 148.12 M | |||
| EBITDA | 2.11 M | |||
| Cash Per Share | 13.81 X | |||
| Total Debt | 94.54 M | |||
| Book Value Per Share | (5.67) X | |||
| Cash Flow From Operations | (32.02 M) | |||
| Earnings Per Share | 0.23 X | |||
| Total Asset | 247.27 M | |||
About Basilea Pharmaceutica Performance
Evaluating Basilea Pharmaceutica's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Basilea Pharmaceutica has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Basilea Pharmaceutica has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company was founded in 2000 and is headquartered in Basel, Switzerland. BASILEA N operates under Pharmaceuticals And Biosciences classification in Switzerland and is traded on Switzerland Exchange. It employs 160 people.Things to note about Basilea Pharmaceutica performance evaluation
Checking the ongoing alerts about Basilea Pharmaceutica for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Basilea Pharmaceutica help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Basilea Pharmaceutica generated a negative expected return over the last 90 days | |
| The company reported the revenue of 148.12 M. Net Loss for the year was (6.83 M) with profit before overhead, payroll, taxes, and interest of 30.89 M. | |
| Basilea Pharmaceutica AG has accumulated about 0 in cash with (32.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.81. |
- Analyzing Basilea Pharmaceutica's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Basilea Pharmaceutica's stock is overvalued or undervalued compared to its peers.
- Examining Basilea Pharmaceutica's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Basilea Pharmaceutica's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Basilea Pharmaceutica's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Basilea Pharmaceutica's stock. These opinions can provide insight into Basilea Pharmaceutica's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Basilea Stock Analysis
When running Basilea Pharmaceutica's price analysis, check to measure Basilea Pharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Basilea Pharmaceutica is operating at the current time. Most of Basilea Pharmaceutica's value examination focuses on studying past and present price action to predict the probability of Basilea Pharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Basilea Pharmaceutica's price. Additionally, you may evaluate how the addition of Basilea Pharmaceutica to your portfolios can decrease your overall portfolio volatility.